Over 70% of France's population has received at least one dose of a COVID-19 vaccine. Emerging research suggests these vaccines offer broader protection beyond SARS-CoV-2.
Coronaviruses pose a major epidemic threat, as evidenced by SARS-CoV-1 (2002), MERS-CoV (2012), and the ongoing SARS-CoV-2 pandemic, which has surpassed 250 million cases and over 5 million deaths worldwide. With around 50 million French people vaccinated against COVID-19, scientists are investigating whether these vaccines confer protection against other coronaviruses.
A study from Northwestern University in Chicago, published in the Journal of Clinical Investigation on October 8, 2021, analyzed plasma samples collected before and after vaccination with Moderna, Pfizer, and Johnson & Johnson vaccines. Results showed significantly elevated anti-SARS-CoV-2 antibodies, as expected. Notably, levels of anti-SARS-CoV-1 and anti-HCoV-OC43 antibodies also increased substantially, while influenza virus antibodies remained unchanged.
To validate these observations, researchers tested mice and observed comparable results in humans. COVID-19 vaccination raised antibodies against SARS-CoV-2, SARS-CoV-1, and HCoV-OC43. Further, mice vaccinated against COVID-19 showed improved tolerance to SARS-CoV-1 infection compared to unvaccinated controls.
These findings are promising, though additional research is essential for confirmation. Tests were conducted shortly after vaccination, and protection wanes over time. Determining long-term cross-protection is challenging due to variables like individual health status and prior coronavirus exposures.
The need for such insights is urgent. A 2020 IPBES report warns of accelerating pandemic frequency, with future outbreaks spreading faster, causing more deaths, and inflicting greater economic damage.
